On October 28, 2026, the U.S. Department of Health and Human Services filed an enforcement discretion policy that, once published in the Federal Register on October 30, will allow state-licensed 503A compounding pharmacies to compound six peptides without the risk of FDA enforcement action, under a specific set of conditions. The six are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. This post explains what the policy is, what it requires and what it leaves open, because patients and prescribers are already asking about it.

Where AccuMix stands: AccuMix Pharmacy is reviewing the policy and its sourcing and reporting requirements and is not currently compounding or dispensing these peptides. We will update this page if that changes.

What the policy is

The document is a notice from HHS (Federal Register document 2026-22192, Docket HHS-OASH-2026-0496), titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” “Enforcement discretion” means the FDA will not take legal action against a state-licensed pharmacy, a federal facility or a licensed physician that compounds one of the six listed peptides in line with the policy’s conditions, while the agency continues work on a formal rule. A two-week public comment period opens on publication.

The six peptides are the same ones the FDA’s Pharmacy Compounding Advisory Committee voted to recommend for the 503A Bulks List in July 2026. The committee voted against a seventh, emideltide (DSIP), which is not covered. The policy applies only to 503A compounding; 503B outsourcing facilities are not addressed.

What it is not

• It is not FDA approval. HHS states that the policy “does not grant FDA approval or establish clinical safety and effectiveness.” None of the six peptides has been shown safe or effective for any use in the FDA’s approval process.
• It is not permanent. The policy applies until the FDA addresses a substance in a final rule, which could include or exclude it, and HHS says it may reconsider if a safety signal or product-quality problem emerges. In 2023 the FDA placed BPC-157 and TB-500 in the category of substances that may not be compounded, citing safety concerns, and much of the agency’s scientific staff reportedly opposed the new policy.
• It is not a change to state law. Compounding is regulated by each state’s board of pharmacy as well as by federal law, and state boards may take their own position on these peptides. A compounding pharmacy must follow the rules of every state it ships to.

The conditions a pharmacy would have to meet

The policy is narrower than the headlines suggest. A pharmacy compounding under it must meet all of the following, in addition to every existing 503A requirement, including a patient-specific prescription for each preparation.

• Source of the active ingredient. The original manufacturer of the peptide must be registered with the FDA and compliant with current good manufacturing practice, with its physical location on the certificate of analysis. A distributor’s registration does not substitute. The certificate must cover identity, potency, impurities and contaminants.
• One ingredient per preparation. The compounded product may contain only a single peptide from the list. Combinations, such as a BPC-157 and TB-500 blend, are outside the policy.
• Specified forms and routes. Appendix B lists the exact salt form and routes of administration permitted for each peptide. Some routes that are common in the marketplace are not included, and epitalon carries an additional limit on course length.
• Oral products need bioavailability data. For an oral preparation, the pharmacy must hold documentation showing adequate human oral bioavailability for the specific formulation it dispenses.
• Reporting. The pharmacy must report what it compounds (ingredient, strength, manufacturer, dosage form and route) to the FDA and to the states where the product is compounded and sent, and must report serious adverse events to the FDA’s MedWatch program and product-quality problems to the FDA and the states.
• Labeling. Every product must be labeled “This is a compounded drug product. Not for resale,” and patients must receive instructions on how to report an adverse event.
• Devices. Any delivery device packaged with the product is limited to an FDA 510(k)-cleared syringe.

What it means for patients and prescribers

For now, the practical effect is that a legal pathway may exist for a narrow set of peptides, in specific forms, from pharmacies that can document FDA-registered sourcing and meet the reporting obligations. It does not mean every peptide sold online is now lawful, and it does not mean a peptide available under the policy has been found safe or effective. Whether any of these products is appropriate for a patient remains a decision for a licensed prescriber.

AccuMix Pharmacy compounds patient-specific preparations under 503A, and we intend to keep doing so by the book in every state we serve. We will follow the Federal Register publication, the comment period and the positions taken by the state boards of pharmacy in our licensed states before deciding whether any of these peptides belongs in our product line. If that happens, we will say so here and on our products page.

Sources

• HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendix B (PDF)
• NBC News, October 28, 2026
• Holland & Knight, “Peptides at a Crossroads”
• American Med Spa Association, FDA peptide interim access policy

This post is general information about a regulatory policy, not medical advice and not an offer to compound or dispense any product. Compounded medications are not FDA-approved. Published October 28, 2026; we will update it as the policy develops.